BIOMX
Company Snapshot
Company Overview
BiomX is a microbiome company working towards the development of phage-based therapies. BiomX is developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis, inflammatory bowel disease, atopic dermatitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
The technology of BiomX relies on finding the best suited phage and using synthetic biology approaches to engineer these phages. The phage cocktail is then optimized in vitro and in vivo for the best activity.
BiomX has several partnerships for the development of microbiome therapeutics:
- BiomX exclusively licensed the access to phage discovery systems and the target bacteria discovery platform from the Weizmann Institute of Science, Israel.
- In collaboration with Takeda, BiomX is developing formulations for its phage therapy manufacturing intermediates and for the final form to be administered.
- BiomX exclusively sub-licensed a set of bacterial targets for the development of phage therapies for the treatment of IBD from JSR Corp.
- In collaboration with Janssen Pharmaceuticals Inc., BiomX is using its XMarker microbiome-based biomarker discovery platform to stratify responders and non-responders to IBD therapeutics.
In Sept. 2020, BiomX entered into a collaboration with Boehringer Ingelheim to use the BiomX XMarker microbiome-based biomarker discovery platform to potentially identify biomarkers associated with patient phenotypes in IBD.
In Oct. 2021, the company entered into a stock purchase agreement with a subsidiary of Maruho Co. Ltd., a leading dermatology focused pharmaceutical company in Japan, pursuant, to which, the Company issued to Maruho 375,000 shares of common stock at a price of $8.00 per share for gross proceeds of $3,000. The company granted Maruho a right of first offer to license its atopic dermatitis product candidate, BX005, in Japan.
In June 2021, a second partnership between Boehringer Ingelheim and BiomX is focused on inflammatory bowel disease (IBD). Using the XMarker discovery platform from Israel-based BiomX, the two businesses will collaborate to find the disease's biomarkers.
BIOMX In News
Company's Business Segments
- Product : BX004, BX211/BX011, Bolt, Xmarker
- Service : Analysis, Research and Development, Clinical Support
Applications/End User Industries
- Healthcare
- Pharmaceuticals
- Biotechnology